Flovent® (Fluticasone) for Horses: Uses, Side Effects & Status in Competition

Fluticasone for horses is an inhaled corticosteroid medication used under veterinary guidance to help manage chronic airway inflammation associated with equine asthma.

Unlike systemic corticosteroids given by mouth or injection, inhaled fluticasone is designed to act locally in the lower airways while limiting exposure to the rest of the body.

Even so, it is not a rescue medication for acute respiratory distress and must be used with proper inhaler technique, an equine-specific delivery device, and veterinary oversight.

Successful management of equine asthma depends on more than medication alone. Keep reading to learn how fluticasone is used in horses, how it is administered, what safety considerations owners should know, and how environmental management supports better respiratory health.

Fluticasone for Horses

Fluticasone, commonly formulated as fluticasone propionate, is a synthetic glucocorticosteroid. ^[1] In human medicine, it is widely used for maintenance treatment of asthma and for allergic or non-allergic nasal inflammation. ^[2]

In equine veterinary medicine, fluticasone is used to help manage chronic airway inflammation and bronchoconstriction associated with equine asthma. ^[3]

Fluticasone has advantages over some older corticosteroids, including strong local activity and limited systemic availability. ^[4] This helps veterinarians provide targeted local dosing while minimizing broader exposure to steroids throughout the body.

The drug is designed to exert a topical effect on the respiratory lining. After inhalation, it penetrates airway cell membranes and acts locally in the lungs. Any medication that is swallowed during administration is largely inactivated by first-pass metabolism in the liver, helping reduce exposure to the rest of the body. ^[3]

Available Forms

Veterinary-specific commercial formulations of fluticasone are not currently available, so equine practitioners rely on human-labeled formulations when prescribing the drug for horses. ^[5]

As such, fluticasone use in horses is considered extra-label, also referred to as off-label, in both the United States and Canada.

Off-label use is permitted under veterinary prescribing regulations, and is performed at the discretion of a licensed veterinarian. Fluticasone is formulated for inhalation or topical mucosal application, but not every human delivery format is suitable for equine use.

Common forms of fluticasone include: ^[3][6][7][8]

• Metered-dose inhalers (MDIs): MDIs are the primary dosage form used in horses. Fluticasone HFA inhalers use a hydrofluoroalkane propellant to deliver a measured mist of medication. The canister must be shaken before use to help ensure a consistent dose.
• Dry powder inhalers (DPIs): DPIs are available in human medicine, but they are not appropriate for horses. These devices rely on the patient taking a strong, voluntary inhalation to draw powder into the lower airways, which horses cannot be trained to do reliably.
• Aqueous nasal sprays: Nasal sprays used for human rhinitis are not used for equine lower airway disease because their larger droplets remain mainly in the upper respiratory tract and do not reach the lungs effectively.

Brand names of human MDI formulations that may be prescribed for horses, depending on country and availability, include: ^[5][7]

• Flovent^® HFA
• Flixotide^® Evohaler
• Generic fluticasone propionate HFA inhalers

×

Enjoy $10 Off From Us

What's your top priority with your horse's health?

🦴 Joint Health 🐎 Hoof Health 💪 Topline & Muscles 🥕 Gut Health & Digestion ⚡ Metabolic Health 🏆 Athletic Performance 🌿 Behavior & Calming 💨 Respiratory Health

• Yes, send me expert advice on horse health and nutrition

* Limit one per customer

Drug Class: Glucocorticoids

Fluticasone belongs to a class of corticosteroids known as glucocorticoids. These drugs mimic the effects of cortisol, a hormone produced by the adrenal glands in response to physiological stress. ^[3]

Glucocorticoids are potent anti-inflammatory and immunosuppressive agents. Unlike non-steroidal anti-inflammatory drugs (NSAIDs), which primarily target cyclooxygenase pathways involved in pain and inflammation, glucocorticoids act more broadly by suppressing multiple parts of the inflammatory cascade. ^[4][5]

Other corticosteroids used or discussed in equine respiratory medicine include: ^[3][5]

• Dexamethasone: A systemic glucocorticoid commonly used for rapid management of severe bronchospasm and airway obstruction. Long-term systemic use carries higher risk of adverse effects, including laminitis and adrenal suppression.
• Prednisolone: An oral systemic glucocorticoid used for longer-term management in some horses. Prednisone, the prodrug of prednisolone, is generally considered less effective in horses because of poor oral bioavailability and limited hepatic conversion.
• Isoflupredone acetate: An injectable corticosteroid that can improve lung function but has mineralocorticoid activity, which may increase the risk of hypokalemia, or dangerously low potassium levels.
• Beclomethasone dipropionate: An older inhaled corticosteroid prodrug. It can be effective for equine asthma, but may have greater systemic absorption than fluticasone.
• Ciclesonide: A newer inhaled prodrug activated within the lung epithelium. High protein binding in circulation helps restrict systemic activity.
• Budesonide: An inhaled corticosteroid that can improve lung function, but may produce systemic absorption and hypothalamic-pituitary-adrenal axis suppression in some asthmatic horses.

Mechanism of Action

Fluticasone propionate works through several related anti-inflammatory mechanisms. Its effects are influenced by high binding affinity for specialized receptors found in many cell types, including airway epithelial cells, macrophages, and smooth muscle cells. ^[4][7][9]

The drug’s molecular structure contributes to its potency. Fluorine atoms increase its ability to pass through pulmonary cell membranes. Once inside the cell, fluticasone binds to glucocorticoid receptors and alters inflammatory signaling. ^[1][9]

Genomic Mechanisms

Some of the sustained anti-inflammatory effects of fluticasone are thought to involve genomic pathways that alter gene transcription and protein synthesis. ^[7] These mechanisms may help explain why fluticasone has a delayed onset of clinical effect and is not used as an emergency rescue medication. ^[3][6]

After inhalation and deposition in the lungs, fluticasone can cross cell membranes and bind to glucocorticoid receptors inside the cells. ^[3][5] The activated drug-receptor complex may then move into the cell nucleus and influence gene expression through two proposed pathways: ^[5][7][9]

• Gene transrepression: This pathway is thought to contribute to anti-inflammatory activity by reducing expression of pro-inflammatory genes. This may decrease production of inflammatory molecules including cytokines, chemokines, and adhesion factors.
• Gene transactivation: The complex may also bind directly to DNA and increase expression of anti-inflammatory genes, such as interleukin-10, and inflammatory pathway inhibitors such as lipocortin-1.

Non-Genomic Mechanisms

Fluticasone may also have rapid, non-genomic effects that occur within minutes of administration. ^[3] These actions are thought to occur through interactions with cell membranes or membrane-bound and cytosolic glucocorticoid receptors. ^[5]

Non-genomic effects may include: ^[5]

• Changes in intracellular calcium levels
• Modulation of reactive oxygen species
• Reduced airway smooth muscle contraction

In horses with asthma, these effects may help reduce airway narrowing and improve airflow by limiting some of the immediate cellular signals that contribute to bronchoconstriction and airway hyperresponsiveness.

However, these rapid effects do not replace the slower anti-inflammatory action needed to manage chronic equine asthma. Fluticasone is still considered a maintenance medication because its main clinical benefit depends on reducing airway inflammation over time. ^[3][5]

Airway Remodeling

Chronic equine asthma is associated with airway remodeling, including: ^[9]

• Increased airway smooth muscle mass
• Extracellular matrix deposition
• Mucus gland enlargement
• Epithelial fragility

Prolonged administration of inhaled fluticasone may help reduce some of these structural changes in the equine lung. ^[9]

Uses in Horses

Disruptions to the horse’s respiratory system can cause chronic coughing, excess mucus production, nasal discharge, exercise intolerance, and increased respiratory effort at rest. Fluticasone is used as a targeted medication for lower respiratory tract inflammation associated with asthma syndromes. ^[3]

Fluticasone is used in equine medicine for treatment of: ^[3]

• Severe equine asthma, historically called recurrent airway obstruction or heaves
• Mild to moderate equine asthma, formerly called inflammatory airway disease
• Summer pasture obstructive pulmonary disease, a seasonal form of asthma associated with heat, humidity, and outdoor airborne allergens

Although systemic glucocorticoids may be used for many immune-mediated conditions in horses, inhaled fluticasone is used specifically for pulmonary disease. ^[10]

Fluticasone is best understood as a maintenance therapy. Research indicates that inhaled fluticasone can help prevent asthma attacks and support clinical remission when horses are exposed to higher-antigen environments. ^[3][5]

However, fluticasone is not the preferred treatment for an acute, severe asthmatic crisis. Compared with intravenous dexamethasone, fluticasone acts more slowly and may require up to 72 hours to produce meaningful improvement, while systemic dexamethasone may provide measurable relief sooner. ^[5]

During acute respiratory distress, severe bronchospasm and mucus can physically block inhaled particles from reaching the smaller airways. In these cases, systemic corticosteroids and other emergency treatments may be required first, with inhaled fluticasone used later for long-term management once airway patency is improved. ^[3][5]

It is important for horse owners to understand that fluticasone does not cure the underlying hypersensitivity of the equine lung. Even with potent anti-inflammatory treatment, airway inflammation may persist if the horse remains exposed to dust, mold, and other triggering antigens. ^[3]

Administration Routes

Fluticasone is administered by inhalation using a human-labeled metered-dose inhaler (MDI) and an equine-specific delivery device. Because commercial fluticasone products are not labeled for horses, dosing must be determined by the supervising veterinarian based on body weight, disease severity, duration of signs, baseline airway obstruction, and clinical response. ^[3]

Horses are obligate nasal breathers and cannot be asked to inhale at the exact moment the canister is deployed. For this reason, the inhaler should not be sprayed directly into the nostril. ^[3]

Instead, the MDI is attached to an equine aerosol delivery device, also called a spacer or holding chamber. Examples include the Equine Haler, AeroHippus Equine Aerosol Chamber, and Flexineb mask system. ^[3]

These devices hold the aerosolized medication in a chamber until the horse breathes in naturally. One-way valves help draw medication into the respiratory tract during inhalation and prevent the horse from exhaling medication back into the chamber. ^[3][6]

Administration Technique

Successful fluticasone therapy depends on the medication reaching the lower airways. Aerosol deposition is affected by particle size, device fit, timing, and spacer maintenance. ^[3]

To support effective delivery: ^[3][6]

• Shake the canister: The MDI should be shaken vigorously for at least five seconds before each dose. Without proper shaking, the drug may not suspend evenly in the propellant.
• Prime when needed: A new inhaler, or one that has not been used for more than seven days, may need to be primed according to veterinary or product instructions.
• Time each dose: The inhaler should be deployed into the spacer immediately before the horse begins to inhale. Releasing the medication while the horse is exhaling can waste the dose.
• Use one pump at a time: Firing multiple puffs into the chamber at once can cause particles to collide, become larger, and fall out of suspension before the horse inhales them.
• Use bronchodilators when prescribed: Horses with visible respiratory effort may need a rapid-acting bronchodilator, such as albuterol, before fluticasone to improve airway opening and medication delivery.
• Maintain the spacer properly: Plastic spacers and masks should be cleaned with mild detergent and allowed to drip dry. Towel drying can create static, causing aerosol particles to stick to the chamber walls instead of reaching the airway.

Bioavailability

The main advantage of fluticasone is its localized respiratory activity and limited systemic bioavailability. ^[3]

Even with good technique, some aerosolized medication impacts the upper respiratory tract, is swallowed, and enters the gastrointestinal tract. ^[3] When swallowed, fluticasone has very low oral bioavailability, and the medication that is absorbed in the tract is rapidly metabolized by the liver. ^[5][7]

The effectiveness of asthma medication use in horses is closely tied to air quality and barn ventilation. Management changes are central to long-term maintenance of equine asthma, including: ^[3]

• Reducing dry hay exposure
• Using low-dust bedding
• Improving ventilation
• Sweeping indoors when horses are turned out
• Ensuring hay is free of mold or other contamination

When fluticasone is combined with environmental dust reduction, horses may experience faster improvement in clinical signs, lung function, and airway inflammation compared with environmental management alone. ^[9]

Storage

Proper storage helps maintain the physical integrity of the pressurized inhaler and the medication suspension.

Storage guidelines include: ^[7][10]

• Temperature: Store the inhaler at controlled room temperature. Freezing or excessive heat can affect the suspension.
• Orientation: Store the inhaler with the plastic mouthpiece facing downward, unless otherwise directed on the product label.
• Heat and puncture hazards: Keep the canister away from direct sunlight, open flames, high heat, and puncture risk. Pressurized aerosol canisters can burst if heated or damaged.
• Safe storage: Keep the inhaler out of reach of children and animals to prevent accidental discharge, chewing, or ingestion.
• Dose tracking: Monitor the dose counter and refill the prescription before it reaches “000.” Some canisters may continue to spray propellant after the medication is depleted.

Safety Warnings & Precautions

Fluticasone has a strong safety profile when used by inhalation under veterinary guidance, but it is not appropriate in every situation. Horses receiving this medication should be monitored for respiratory response, local irritation, and signs that their condition is worsening rather than improving. ^[5]

Contraindications

Contraindications are circumstances where a medication should be avoided or used only with special veterinary caution.

Inhaled fluticasone may be contraindicated in horses with: ^[5]

• Acute bronchospasm or respiratory distress: Fluticasone should not be used as the primary rescue medication for life-threatening wheezing, severe bronchospasm, or profound difficulty breathing. It is a maintenance controller, not a rapid-acting bronchodilator.
• Active respiratory infection: Fluticasone should not be used when respiratory distress is caused by severe active bacterial, viral, or fungal infection, unless otherwise directed by a licensed veterinarian. Local immunosuppression may worsen infection if appropriate antimicrobial or supportive treatment is not provided.
• Known hypersensitivity: Fluticasone should be avoided in horses with a known allergic or hypersensitivity reaction to fluticasone, HFA propellants, or other inhaler ingredients.

Using an inhaler is not a substitute for veterinary assessment. Coughing, labored breathing, nasal discharge, poor performance, and increased respiratory effort can have many causes, and the appropriate treatment depends on the diagnosis.

Fluticasone inhalers should also not be shared between horses. Each horse needs an individual veterinary prescription, and sharing inhalers or masks can lead to incorrect dosing, delayed diagnosis, cross-contamination, or inappropriate treatment of a different respiratory condition.

Side Effects

When administered at appropriate therapeutic doses by inhalation, fluticasone is generally well-tolerated by horses. Inhaled delivery helps avoid many side effects associated with chronic systemic corticosteroid use, including muscle wasting, insulin resistance, altered bone metabolism, polyuria (excessive urination), and polydipsia (excessive thirst). ^[3]

Even so, owner monitoring remains important, especially during long-term treatment.

Hypothalamic-Pituitary-Adrenal Axis

Suppression of the hypothalamic-pituitary-adrenal (HPA) axis is a known side effect of systemic glucocorticoid use. This means ongoing use of systemic glucocorticoids can reduce the horse’s natural cortisol production through negative feedback at the hypothalamus and pituitary gland. ^[3][5]

Research suggests standard therapeutic doses of inhaled fluticasone do not significantly suppress the HPA axis, allowing horses to maintain normal basal cortisol levels and respond appropriately to stress. ^[3]

Long-term high-dose exposure may eventually produce measurable cortisol suppression, but this appears uncommon and may not be accompanied by clinical illness. ^[3]

Immune Function

A key concern with corticosteroid therapy is systemic immunosuppression, which can increase vulnerability to infection. Long-term studies of asthmatic horses treated with inhaled fluticasone for up to 11 months found no significant harmful effects on innate or adaptive immune function. ^[3]

Horses maintained on long-term fluticasone have also been able to mount antibody responses to routine vaccinations, including tetanus toxoid and multivalent viral antigens. ^[9] This suggests inhaled fluticasone may not have the same immunosuppressive effects as systemic glucocorticoid use.

Laminitis Risk

Some systemic glucocorticoids have historically been associated with laminitis in at-risk horses. ^[3][5] Available literature suggests that laminitis associated with inhaled fluticasone is very rare, making inhaled therapy a preferred option for some asthmatic horses with metabolic risk factors such as Equine Metabolic Syndrome or Pituitary Pars Intermedia Dysfunction. ^[3]

Horses with a history of laminitis risk factors should still be monitored closely when any corticosteroid is prescribed.

Local & Systemic Side Effects

Most side effects associated with inhaled fluticasone are local and mild, but owners should monitor the horse’s respiratory comfort, muzzle skin, and overall condition.

Potential side effects include: ^[3][5]

• Respiratory irritation: Some horses may cough briefly after inhaling the aerosol. This is often transient, but persistent or worsening coughing should be discussed with a veterinarian.
• Skin irritation: Long-term mask use and local steroid deposition may occasionally contribute to focal hair loss, redness, sores, or skin thinning around the muzzle. The mask should be cleaned regularly and fitted correctly.
• Signs of systemic steroid exposure: Contact your veterinarian if your horse develops increased thirst, increased urination, abnormal weight gain, a potbellied appearance, or unexplained weakness.

Acute Toxicity (Overdose)

Overdose through normal inhalation is unlikely when the medication is administered as prescribed. ^[5][6] However, severe toxic effects may occur if a horse chews or ingests the pressurized inhaler canister.

If a horse eats or punctures the canister, contact your veterinarian or an animal poison control center immediately.

Drug Interactions

Fluticasone relies on metabolism in the liver to neutralize swallowed medication before it reaches systemic circulation. Drugs that strongly inhibit these pathways, including some systemic antifungal medications such as ketoconazole or itraconazole, may increase systemic fluticasone exposure. ^[5][10]

If metabolism is inhibited, more fluticasone may enter circulation, increasing the risk of systemic corticosteroid effects such as adrenal suppression. ^[10]

Intro to Equine Nutrition

Gain a deeper understanding of your horse's nutrition needs. This free introductory course provides a foundation for horse owners to learn how to balance your horse's diet.

Enroll Now

Regulatory Status & Legal Considerations

Fluticasone products are approved for human use by regulatory agencies including the U.S. Food and Drug Administration (FDA), Health Canada, and other international drug authorities. These approvals apply to human-labeled products, not to equine-specific formulations or labeled veterinary use in horses. ^[5][7]

Because there is no fluticasone product specifically approved for horses, use in equine patients is considered extra-label, also called off-label use. Extra-label use is permitted under veterinary prescribing rules when a veterinarian determines the medication is appropriate for the individual animal and uses it within the requirements of a valid veterinarian-client-patient relationship.

Owners should only use fluticasone in horses under veterinary direction. The prescribing veterinarian is responsible for selecting the product, delivery method, dose, treatment schedule, monitoring plan, and any competition or withdrawal considerations that apply to the horse.

Status in Competition

Fluticasone is regulated in equine competition, and the rules vary by organization, discipline, and jurisdiction. In some competitions, withdrawal times or medication reporting requirements may apply.

Under FEI rules, fluticasone is listed as a banned substance, and detection in a competition horse may result in disqualification or sanctions. ^[11]

Owners should work with their veterinarian before using fluticasone in any horse that may compete. The veterinarian can help confirm current rules, determine whether treatment is appropriate, advise on withdrawal guidance, and complete any required medication documentation before the horse enters competition.

Frequently Asked Questions

Here are some frequently asked questions about fluticasone for horses:

Summary

Fluticasone is an inhaled corticosteroid used off-label to help manage chronic airway inflammation in horses with equine asthma. It works best as part of a broader plan that includes correct inhaler use, monitoring, and environmental dust control.

• Fluticasone is used as a maintenance therapy for equine asthma, not as an emergency rescue medication
• It is typically delivered by metered-dose inhaler with an equine-specific spacer or mask
• Inhaled delivery helps target the lower airways while limiting systemic steroid exposure
• Side effects are usually mild, but horses should be monitored during long-term treatment
• Competition rules vary, and fluticasone may be restricted or prohibited by some organizations